Trial · NCT02608177
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
NCT02608177, Not applicable, Completed, University of Washington; results first posted 2018-09-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management. Trials, record NCT02608177. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02608177
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
- NCT number
- NCT02608177
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 3 participants, actual
- Lead sponsor
- University of Washington
- Conditions
- Chronic Kidney Diseases, Type 2 Diabetes
- Interventions
- Linagliptin, Glipizide
- First posted
- 2015-11-18
- Last updated
- 2018-10-12
- Results first posted
- 2018-09-13
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Glucose Time in Range | last 6 days of each 28-day treatment period | Time with glucose 70-140 mg/dL |
| Secondary | Glycemic Variability | last 6 days of each 28-day treatment period | SD of glucose readings |
| Secondary | Hypoglycemia | last 6 days of each 28-day treatment period | Glucose \<70 mg/dL for at least 10 minutes |
| Secondary | Biomarkers of Systemic Inflammation | last 6 days of each 28-day treatment period | Measured by plasma C-reactive protein (CRP) |
| Secondary | Biomarkers of Systemic Inflammation | last 6 days of each 28-day treatment period | Measured by plasma interleukin-6 |
| Secondary | Biomarkers of Oxidative Stress | last 6 days of each 28-day treatment period | Measured by plasma F2-isoprostanes |
| Secondary | Biomarkers of Oxidative Stress | last 6 days of each 28-day treatment period | Measured by urine F2-isoprostanes |
| Secondary | Biomarkers of Albuminuria | last 6 days of each 28-day treatment period | Measured by albumin-creatinine ratio |
Source ClinicalTrials.gov
Outcomes8
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Glucose Time in Range | last 6 days of each 28-day treatment period | minutes per day | MEAN | |
| SECONDARY | Glycemic Variability | last 6 days of each 28-day treatment period | mg/dL | MEAN | |
| SECONDARY | Hypoglycemia | last 6 days of each 28-day treatment period | events | NUMBER | |
| SECONDARY | Biomarkers of Systemic Inflammation | last 6 days of each 28-day treatment period | Labs not run due to small sample size. | ||
| SECONDARY | Biomarkers of Systemic Inflammation | last 6 days of each 28-day treatment period | Labs not run due to small sample size. | ||
| SECONDARY | Biomarkers of Oxidative Stress | last 6 days of each 28-day treatment period | Labs not run due to small sample size. | ||
| SECONDARY | Biomarkers of Oxidative Stress | last 6 days of each 28-day treatment period | Labs not run due to small sample size. | ||
| SECONDARY | Biomarkers of Albuminuria | last 6 days of each 28-day treatment period | Labs not run due to small sample size. |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Glucose Time in Range | Glipizide | 495.2 | Standard Deviation 671.9 | minutes per day | |
| Glucose Time in Range | Linagliptin | 573.3 | Standard Deviation 669.1 | minutes per day | |
| Glycemic Variability | Glipizide | 40.9 | Standard Deviation 16.1 | mg/dL | |
| Glycemic Variability | Linagliptin | 41.5 | Standard Deviation 22.7 | mg/dL | |
| Hypoglycemia | Glipizide | 4 | events | ||
| Hypoglycemia | Linagliptin | 2 | events |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Linagliptin/Glipizide | 2 | |
| Overall Study | STARTED | Glipizide/Linagliptin | 1 | |
| Overall Study | COMPLETED | Linagliptin/Glipizide | 2 | |
| Overall Study | COMPLETED | Glipizide/Linagliptin | 1 | |
| Overall Study | NOT COMPLETED | Linagliptin/Glipizide | 0 | |
| Overall Study | NOT COMPLETED | Glipizide/Linagliptin | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Linagliptin/Glipizide | 0 | 2 |
| Total, all-cause mortality | Glipizide/Linagliptin | 0 | 1 |
| Total, other adverse events | Linagliptin/Glipizide | 0 | 2 |
| Total, other adverse events | Glipizide/Linagliptin | 0 | 1 |
| Total, serious adverse events | Linagliptin/Glipizide | 0 | 2 |
| Total, serious adverse events | Glipizide/Linagliptin | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Linagliptin/Glipizide vs Glipizide/Linagliptin: deaths from any cause | Trial comparisons |
| Linagliptin/Glipizide vs Glipizide/Linagliptin: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02608177
GET https://conductscience.org/api/trials/v1/NCT02608177/registered